Homo luzonensis : principales caractéristiques et implications pour l’histoire évolutionnaire du genre

La nouvelle espèce Homo luzonensis a été décrite en 2019 à partir d’un assemblage constitué de treize éléments fossiles découverts dans la grotte de Callao (île de Luzon, Philippines) en 2007, 2011 et 2015. La datation directe de deux de ces fossiles par les séries de l’uranium indique des âges minimums respectifs de 50 000 et 67 000 ans. Dans cette présentation, nous montrons que ces spécimens présentent une combinaison de caractéristiques morphologiques primitives (i.e. ressemblant à Austra..

Book review: "Unearthing prehistory: The archaeology of Northeastern Luzon, Philippine islands". Armand Salvador Mijares. 2007

The book "Unearthing Prehistory: The Archaeology of Northeastern Luzon, Philippine Islands" tells the story of 50 years of archaeology in Northeastern Luzon. It discusses known archaeological information as well as it investigates different hypotheses and other important unresolved questions in the region

Quenched and self-tempered (Q.S.T.) reinforcing rod on Montereau high speed mill

Translated from French (Cah. Inf. Tech./Rev. Metall. 1988 v. 85(12) p. 961-966)SIGLEAvailable from British Library Document Supply Centre- DSC:9022.06(BISI-Trans--27468)T / BLDSC - British Library Document Supply CentreGBUnited Kingdo

Nivolumab-refractory patients with advanced non-small-cell lung cancer

International audienceIntroduction: Immune checkpoint inhibitors (ICIs) have revolutionised cancer care especially in lung cancer. New response patterns have been described under ICIs such as pseudo-progression or hyper-progressive disease (HPD). The definition of HPD is yet to be consensual. The aim of this study was to suggest a clinical definition of nivolumab-refractory patients and find factors associated with this entity.Methods: We performed a multi centric retrospective study including all patients who received nivolumab for the treatment of advanced non-small cell lung cancer (NSCLC) during the French authorisation for temporary use in 2015.Results: 303 patients were included in the cohort and 292 had details on the number of nivolumab injections received. 57 patients (20%) were nivolumab-refractory. These patients had worse PS at nivolumab initiation (p < 0.0001), shorter duration of treatment before nivolumab (p = 0.028) and had dramatically shorter nivolumab overall survival (p < 0.0001) than patients who did not present with refractory disease.Conclusion: Nivolumab-refractory disease can affect up to 20% of patients treated with nivolumab for advanced NSCLC with dramatically shortened survival rates. Further studies are needed to understand the precise mechanisms leading to refractory disease as well as its management

The first evidence for Late Pleistocene dogs in Italy

The identification of the earliest dogs is challenging because of the absence and/or mosaic pattern of morphological diagnostic features in the initial phases of the domestication process. Furthermore, the natural occurrence of some of these characters in Late Pleistocene wolf populations and the time it took from the onset of traits related to domestication to their prevalence remain indefinite. For these reasons, the spatiotemporal context of the early domestication of dogs is hotly debated. Our combined molecular and morphological analyses of fossil canid remains from the sites of Grotta Paglicci and Grotta Romanelli, in southern Italy, attest of the presence of dogs at least 14,000 calibrated years before present. This unambiguously documents one of the earliest occurrence of domesticates in the Upper Palaeolithic of Europe and in the Mediterranean. The genetic affinity between the Palaeolithic dogs from southern Italy and contemporaneous ones found in Germany also suggest that these animals were an important common adjunct during the Late Glacial, when strong cultural diversification occurred between the Mediterranean world and European areas north of the Alps. Additionally, aDNA analyses indicate that this Upper Palaeolithic dog lineage from Italy may have contributed to the genetic diversity of living dogs

Premières journées francophones des utilisateurs de système d’aide à la décision en pharmacie clinique : retour d’expériences et perspectives [First French-speaking days of users of decision support system in clinical pharmacy: Feedback and perspectives]

Clinical decision support systems (CDSS) are tools that have been used for several years by clinical pharmacy teams to support pharmaceutical analysis, with a perspective of contributing to the quality of care in collaboration with the other health care team members. These tools require both technical, logistical and human resources. The growing use of these systems in different establishments in France and in Europe gave birth to the idea of meeting to share our experiences. The days organized in Lille in September 2021 aimed at proposing a time of exchange and reflection on the use of these CDSS in clinical pharmacy. A first session was devoted to feedback from each establishment. These tools are essentially used to optimize pharmaceutical analysis and to secure patient medication management. This session outlined the clear advantages and common limitations of these CDSS. Two research projects were also presented to put the use of these tools into perspective. The second session of these days, in the form of workshops, addressed 4 themes that surround the implementation of CDSS: their usability, the legal aspect, the creation of rules and their possible valorization. Common problems were raised, the resolution of which requires close collaboration. This is a first step proposing a beginning of harmonization and sharing that should be deepened in order not to lose the dynamics created between the different centers. This event ended with the proposal to set up two working groups around these systems: the creation and structuring of rules for the detection of risk situations and the common valorization of the work